To identify promising therapeutic candidates for AD, we conducted MD simulations to evaluate the binding interactions between seven drug candidates with predicted BBB permeability (Vorapaxar, Bictegravir, Tonaftate, Fluspirilene, Lisuride, Lasmiditan, and Olaparib) and five DER protei targets (ZEB2, APP, PAX6, ETV6, and ST18). This evidence concerns the gene APP and Alzheimer disease.